Calaspargase Pegol-mknl

Brand name: Asparlas

Calaspargase Pegol

Use of Calaspargase Pegol-mknl in Cancer Treatment

Calaspargase pegol-mknl is authorized to treat the following conditions:

Acute lymphoblastic leukemia is a kind of leukemia that affects children and young people aged one month to twenty-one years. It’s a drug that’s used in conjunction with other drugs to treat cancer.

Calaspargase pegol-mknl is also being researched for its use in the treatment of various cancers.


With possible antineoplastic action, an intravenous formulation comprising E. coli-derived L-asparaginase II coupled with succinimidyl carbonate monomethoxypolyethylene glycol (SC-PEG). L-asparaginase converts L-asparagine to L-aspartic acid and ammonia, depleting asparagine in cells. Asparagine depletion inhibits protein synthesis and tumor cell growth, particularly in the G1 phase of the cell cycle, and eventually leads to tumor cell death. Asparagine is essential for protein synthesis in acute lymphoblastic leukemia (ALL) cells, which lack the enzyme asparagine synthase and so cannot manufacture this amino acid.

Pegylation reduces enzyme antigenicity while also lengthening its half-life. SC is utilized as a PEG linker to aid in the attachment of asparaginase and to improve the formulation’s stability.